Poster

Modeling CAR-T Outcomes in Multiple Myeloma

Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…

Certara2026 年 5 月 4 日

Poster

Modeling T-cell Exhaustion in Immunotherapy

Discover how QSP modeling predicts T-cell exhaustion, relapse risk, and optimal dosing strategies for T-cell…

Certara2026 年 5 月 4 日

Poster

Modeling Hematopoiesis in MDS and AML with QSP

Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…

Certara2026 年 5 月 1 日

Poster

IO Simulator: A QSP Platform for Immuno-Oncology

This poster showcases how IO Simulator predicts immunotherapy response and supports combination design and biomarker…

Certara2026 年 4 月 30 日

Blog

From models to impact: What QSPC 2026 revealed about the future of drug development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

Certara2026 年 4 月 28 日

Blog

Top 10 benefits of Simcyp® Simulator for drug development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 23 日 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

Certara2026 年 4 月 23 日

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

Certara2026 年 4 月 10 日

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

Certara2026 年 4 月 7 日

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

Certara2026 年 4 月 2 日

建模与模拟

Modeling CAR-T Outcomes in Multiple Myeloma

Modeling T-cell Exhaustion in Immunotherapy

Modeling Hematopoiesis in MDS and AML with QSP

IO Simulator: A QSP Platform for Immuno-Oncology

From models to impact: What QSPC 2026 revealed about the future of drug development

Top 10 benefits of Simcyp® Simulator for drug development

ADC dose optimization: Applying model-informed strategies in development

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

订阅时事通讯

快捷链接

解决方案

联系我们